fbpx

News

Lundbeckfonden Ventures News

  NBS System now available to US patients for both motor and speech mapping of the cortex Helsinki, Finland — Nexstim Oy, a medical device company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the NexSpeech® module for use with the Navigated Brain Stimulation (NBS) System. In presurgical planning for patients with...
Additional Presentations at ATC Will Provide Supporting Evidence of the Activity and Tolerability of LCP-Tacro in Kidney and Liver Transplant Patients   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests that these patients may be safely...
The appointment of Key Opinion Leader (KOL) in Allergy and Immunology is of strategic importance to DBV   BAGNEAUX, France, May 31, 2012 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Pr. Hugh Sampson to its world-class Scientific Advisory...
Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients at moderate-to-high risk of suffering PONV. Vomiting and especially nausea remain a major problem...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it contemplates restructuring the company’s operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-TacroT, Veloxis’ product candidate for the prevention of organ rejection. It is planned that a discontinuation of other pipeline activities will take place, including...
 MPM Capital and LSP Life Sciences Partners join existing Celladon investment syndicate – Total capital proceeds of recent investment round increased to $53 million San Diego, California, May 7, 2012/PRNewswire/ — Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced the receipt of additional capital proceeds...
  BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that it has been selected as a Top 100 Winner for Red Herring's 2012 Europe Award, a prestigious list honoring the year's most promising private technology ventures from the European business region....
  Lund, SWEDEN, BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic replacement surgeries, today announced the appointment of Andreas Muchowski to the position of Vice President of Sales Germany. Andreas will lead sales recruiting efforts and prepare for the upcoming market launch of exciting...
Sunnyvale, CA, Asante Solutions, Inc. (Asante), a medical device company focused on diabetes care, has strengthened its leadership team by adding David Thrower as president and chief executive officer, and Eric Steuben as vice president of operations. Former President and Chief Executive Officer Phil Hopper will remain as a special advisor and board member.  ...
1 56 57 58 59 60 62

Lundbeckfonden Ventures

Nyheder

Acacia Pharma Group PLC – Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals
13. January 2020
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
13. January 2020
Christine Soden to step down and Gary G. Gemignani to be appointed as new CFO
13. January 2020